Comparative Study
doi: 10.1016/s0140-6736(77)91366-6.
High remission-induction rate in acute myeloid leukaemia
- PMID: 65605
- DOI: 10.1016/s0140-6736(77)91366-6
Item in Clipboard
Comparative Study
High remission-induction rate in acute myeloid leukaemia
Lancet.
.
Abstract
28 adult patients with acute myeloid leukaemia (A.M.L.) received T.A.D., a high-dose sequential chemotherapeutic remission-induction regimen consisting of 7-day courses of cytosine arabinoside, 6-thioguanine, and daunorubicin. Overall response-rate was 82%. 22 patients (79%) achieved complete remission, and 1 had a partial remission. Median remission duration was 280 days and median survival 375 days. 10 patients remain in remission. These induction results are superior to those reported in most studies and indicate that disease remission can be achieved in a high proportion of patients with A.M.L. treated with an intensive multi-agent chemotherapeutic regimen, provided support facilities are adequate.
Similar articles
-
[Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia].Bull Cancer. 1974 Jul-Sep;61(3):411-8. Bull Cancer. 1974. PMID: 4533741 Clinical Trial. French. No abstract available.
-
Preliminary results of a trial on acute myeloid leukemia comparing the effect of cytosine arabinoside, the combination of cytosine arabinoside and thioguanine and the combination of cytosine arabinoside and daunorubicine.Recent Results Cancer Res. 1973;43:165-8. Recent Results Cancer Res. 1973. PMID: 4531077 No abstract available.
-
The effect of thioguanine on a combination of daunorubicine, cytarabine and prednisone in the treatment of acute leukaemia in adults. The Finnish Leukaemia Group.Scand J Haematol. 1979 Aug;23(2):124-8. Scand J Haematol. 1979. PMID: 291122 Clinical Trial.
-
Management of acute leukemia in adults.Med Pediatr Oncol. 1975;1(2):149-58. doi: 10.1002/mpo.2950010210. Med Pediatr Oncol. 1975. PMID: 778572 Review.
-
Are we curing acute myelogenous leukemia?Leuk Res. 1993 Dec;17(12):1071-2. doi: 10.1016/0145-2126(93)90165-h. Leuk Res. 1993. PMID: 8246611 Review. No abstract available.
Cited by
-
Razoxane in treatment of acute myeloid leukaemia.Br Med J. 1978 Oct 14;2(6144):1089-90. doi: 10.1136/bmj.2.6144.1089-d. Br Med J. 1978. PMID: 280401 Free PMC article. No abstract available.
-
Remission induction and remission maintenance in adult acute nonlymphocytic leukemia employing a modified cytostatic (COAP) regimen.Blut. 1979 Jul;39(1):39-45. doi: 10.1007/BF01008073. Blut. 1979. PMID: 465742
-
Chemotherapy of the myeloid leukaemias.J R Coll Physicians Lond. 1980 Jan;14(1):36-41. J R Coll Physicians Lond. 1980. PMID: 7003128 Free PMC article. Clinical Trial.
-
The nucleotide-permeable Escherichia coli cell, a sensitive DNA repair indicator for carcinogens, mutagens, and antitumor agents binding covalently to DNA.Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1978 Sep 28;92(2):177-214. doi: 10.1007/BF00312409. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1978. PMID: 151998
-
[Bone marrow transplantation for relapsed, acute leukaemia (author's transl)].Klin Wochenschr. 1981 Mar 16;59(6):251-66. doi: 10.1007/BF01478204. Klin Wochenschr. 1981. PMID: 7015003 German.